Northwest Biotherapeutics (NWBO) Construction in Progress (2015 - 2017)

Northwest Biotherapeutics' Construction in Progress history runs 3 years deep, the most recent figure standing at $47.3 million for Q4 2017.

• On a quarterly basis, Construction in Progress rose 6.19% year-over-year to $47.3 million in Q4 2017; TTM through Dec 2017 was $47.3 million, a 6.19% increase from a year earlier, with the FY2017 full-year figure at $47.3 million, up 6.19% from the prior year.
• Construction in Progress held at $47.3 million in Q4 2017 per NWBO's latest filing, from $47.3 million in the prior quarter.
• Across five years, Construction in Progress topped out at $47.3 million in Q3 2017 and bottomed at $44.6 million in Q4 2016.
• The 3-year median for Construction in Progress is $46.0 million (2015), against an average of $46.0 million.
• Across the five-year window, Construction in Progress decreased 2.46% in 2016 and grew 6.19% in 2017, its largest moves.
• Year by year, Construction in Progress stood at $45.7 million in 2015, then fell by 2.46% to $44.6 million in 2016, then rose by 6.19% to $47.3 million in 2017.
• Per Business Quant, the three latest NWBO Construction in Progress figures stand at $47.3 million (Q4 2017), $47.3 million (Q3 2017), and $46.2 million (Q2 2017).